Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab plus methotrexate versus methotrexate alone in methotrexate-naive active psoriatic arthritis
2005-002189-12Phase 3Completed
- Sponsor
- Integrated Therapeutics Group
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in psoriatic arthritis (PsA) comparing Infliximab plus methotrexate with Methotrexate alone (2 arms). Primary endpoint: ACR20 response at week 16. Started Oct 2005; status: completed.
02
Drugs
infliximabmethotrexate
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2005-002189-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002189-12.